A Phase 3 interventional study of Tocilizumab and Prednisone in Giant Cell Arteritis, sponsored by Hoffmann-La Roche. Completed at 78 sites in 14 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-02-06.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing tocilizumab in Giant Cell Arteritis — 2 open to participants now, 3 under way, 1 of them phase 3. tocilizumab · Giant Cell Arteritis.
Among the 12 studies testing tocilizumab in Giant Cell Arteritis, this one is the 2nd largest by enrollment, is the only one that started in 2013, is one of 3 in phase 3, and was the 2nd registered.
149 studies on the registry are indexed under Giant Cell Arteritis; 50 are open to participants now.
Browse Giant Cell Arteritis studies →2 of the 12 studies testing tocilizumab in Giant Cell Arteritis are open now, in 1 country. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 50+
NYU Langone Health · Sites in United States
Ages 18+
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 36 Giant Cell Arteritis studies recruiting now, 34 (94%) set no upper age limit and none (0%) stop at 75 or younger; 4 take children under 18; 9 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 3 · Phase 4 2
First in 2011; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 251 is above the median of 64 across 65 interventional studies indexed under Giant Cell Arteritis.
Median enrollment 44 across the 12 interventional studies. Of the 7 that completed or were terminated, 4 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 12 have an industry lead sponsor. The 9 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 4 studies filed under Giant Cell Arteritis — fewer than ten, so there is no comparison to draw.
1 of the studies testing tocilizumab in Giant Cell Arteritis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07108387National Institute of Allergy and Infectious Diseases (NIAID)Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis | 2027-06-11 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing tocilizumab in Giant Cell Arteritis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of tocilizumab in participants with GCA. The study will consist of 2 parts: a 52-week double-blind treatment period (Part 1) followed by a 104-week open label long-term follow-up period (Part 2). In Part 1 of the study eligible participants will be randomized to receive either tocilizumab every week (qw) or every 2 weeks (q2w) or placebo for 52 weeks, with tapering oral daily doses of prednisone. After Week 52, participants in remission will stop study treatment and enter long-term follow-up, whereas participants with disease activity or flares will receive open-label tocilizumab or other treatment at the discretion of the investigator for a maximum period of 104 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive tocilizumab at a dose of 162 milligrams (mg) as subcutaneous (SC) injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
Drug: Tocilizumab · Drug: Prednisone · Drug: Prednisone Placebo
Participants will receive tocilizumab at a dose of 162 mg as SC injection q2w (and tocilizumab placebo q2w starting from Week 2) up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
Drug: Tocilizumab · Drug: Prednisone · Drug: Tocilizumab Placebo · Drug: Prednisone Placebo
Participants will receive tocilizumab placebo as SC injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to the protocol-defined schedule. Participants will receive prednisone tapering oral daily doses during the first 26 weeks and prednisone placebo from Week 26 up to Week 52.
Drug: Prednisone · Drug: Tocilizumab Placebo · Drug: Prednisone Placebo
Participants will receive tocilizumab placebo as SC injection qw up to 52 weeks along with prednisone and/or prednisone placebo according to a protocol-defined schedule. Participants will receive prednisone tapering oral daily doses for 52 weeks.
Drug: Prednisone · Drug: Tocilizumab Placebo · Drug: Prednisone Placebo
Participants without sustained remission at Week 52 will receive open-label tocilizumab at a dose of 162 mg as SC injection qw and/or corticosteroids and/or methotrexate at the discretion of the investigator for a maximum of 104 weeks.
Drug: Tocilizumab · Drug: Corticosteroids · Drug: Methotrexate
Tocilizumab will be administered at a dose of 162 mg as SC injection qw or q2w for 52 weeks in Part 1 of the study and at a dose 162 mg as SC injection qw for 104 week at the discretion of the investigator in Part 2 of the study.
Also known as: RoActemra, Actemra, RO4877533
Prednisone will be administered at tapering oral doses as tablets daily for 26 or 52 weeks according to the protocol-defined schedule in Part 1 of the study. Prednisone will also be administered as escape therapy to treat disease flares in an open-label manner during Part 1 at a dose and duration selected by the investigator.
Tocilizumab placebo will be administered as SC injection qw or q2w for 52 weeks in Part 1 of the study.
Prednisone placebo will be administered as tablets orally daily according to the protocol-defined schedule (from Week 26 to Week 52) in Part 1 of the study.
Participants without sustained remission at Week 52 will receive corticosteroids at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
Participants without sustained remission at Week 52 will receive methotrexate at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 26 Weeks Prednisone Taper)
Remission was defined as the absence of flare and normalization of the C-reactive protein (CRP) (less than \[\<\] 1 milligram per deciliter \[mg/dL\]). Sustained remission was defined as the absence of flare following induction of remission within 12 weeks of randomization and maintained up to Week 52. Flare was determined by the investigator and was defined as the recurrence of signs or symptoms of GCA and/or erythrocyte sedimentation rate (ESR) greater than or equal to (\>/=) 30 millimeters per hour (mm/hr) attributable to GCA. A single CRP elevation (\>/=1 mg/dL) was not considered as a sign of flare, unless the CRP remained elevated (\>/=1 mg/dL) at the next study visit.
Time frame: Week 52
Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 52 Weeks Prednisone Taper)
Remission was defined as the absence of flare and normalization of the CRP (\<1 mg/dL). Sustained remission was defined as the absence of flare following induction of remission within 12 weeks of randomization and maintained up to Week 52. Flare was determined by the investigator and was defined as the recurrence of signs or symptoms of GCA and/or ESR \>/=30 mm/hr attributable to GCA. A single CRP elevation (\>/=1 mg/dL) was not considered as a sign of flare, unless the CRP remained elevated (\>/=1 mg/dL) at the next study visit.
Time frame: Week 52
Time to First GCA Disease Flare
Flare was determined by the investigator and was defined as the recurrence of signs or symptoms of GCA and/or ESR \>/=30 mm/hr attributable to GCA. Participants who withdrew from the study prior to Week 52 were censored from the time of withdrawal.
Time frame: Up to 52 weeks
Total Cumulative Prednisone Dose
The median total cumulative prednisone dose over the 52 weeks for each treatment group and the corresponding 95% confidence intervals are presented.
Time frame: Up to 52 weeks
Change From Baseline in Short Form (SF)-36 Questionnaire Score at Week 52
The SF-36 is a standardized questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical Component Score (PCS) and Mental Component Score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A positive change from baseline indicates improvement. No imputation was used for missing data. Data was set to missing for participants who received escape therapy.
Time frame: Baseline, Week 52
Change From Baseline in Patient Global Assessment (PGA) of Disease Activity Assessed Using Visual Analogue Scale (VAS) at Week 52
Participants assessed their current disease activity on a 0-100 millimeter (mm) VAS, where 0 mm = no disease activity and 100 mm = maximum disease activity. A negative change from baseline indicates improvement.
Time frame: Baseline, Week 52
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Steady State of Tocilizumab
AUCtau is the model-predicted area under the tocilizumab serum concentration versus time curve from time zero to the end of dosing interval. AUCtau is measured in microgram\*day per milliliter (mcg\*day/mL).
Time frame: Baseline and Week 16 (Predose [Hour 0], 24, 48, 72, 96, and 120 or 144 hours postdose); Weeks 1, 2, 17, and 18 (Predose [Hour 0])
Maximum Serum Concentration at Steady State (Cmax,ss) of Tocilizumab
Cmax,ss is maximum model-predicted serum steady state concentration of tocilizumab measured in micrograms per milliliter (mcg/mL).
Time frame: Baseline and Week 16 (Predose [Hour 0], 24, 48, 72, 96, and 120 or 144 hours postdose); Weeks 1, 2, 17, and 18 (Predose [Hour 0])
Minimum Serum Concentration at Steady State (Cmin,ss) of Tocilizumab
Cmin,ss is minimum model-predicted serum steady state concentration of tocilizumab measured in mcg/mL.
Time frame: Baseline and Week 16 (Predose [Hour 0], 24, 48, 72, 96, and 120 or 144 hours postdose); Weeks 1, 2, 17, and 18 (Predose [Hour 0])
Minimum Observed Serum Concentration (Ctrough) of Tocilizumab
Ctrough is minimum observed serum concentration of tocilizumab measured in mcg/mL.
Time frame: Predose (Hour 0) at Baseline and Week 52
Serum Interleukin-6 (IL-6) Level
Time frame: Baseline and Week 52
Serum Soluble IL-6 Receptor (sIL-6R) Level
Time frame: Baseline and Week 52
Erythrocyte Sedimentation Rate (ESR)
ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hr. A higher rate is consistent with inflammation.
Time frame: Baseline and Week 52
C-Reactive Protein (CRP) Level
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
Time frame: Baseline and Week 52
Percentage of Participants With Anti-Tocilizumab Antibodies
All samples were tested by screening assay, and those samples that were positive were further analyzed by a confirmation assay to confirm specificity. Percentage of participants who has a positive confirmation assay result any time after the initial drug administration with a negative confirmation assay result at baseline was reported.
Time frame: Baseline up to Week 52
The study consists of 2 parts: a 52-week double-blind treatment period (Part 1) followed by a 104-week open label long-term follow-up period (Part 2).
| Milestone | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | Part 1: Placebo + 26 Weeks Prednisone Taper | Part 1: Placebo + 52 Weeks Prednisone Taper | Part 2: No Tocilizumab (Placebo in Part 1) | Part 2: No Tocilizumab (Tocilizumab in Part 1) | Part 2: Tocilizumab (Placebo in Part 1) | Part 2: Tocilizumab (Tocilizumab in Part 1) |
|---|---|---|---|---|---|---|---|---|
| Started | 100 | 49 | 50 | 51 | 0 | 0 | 0 | 0 |
| Completed | 85 | 41 | 44 | 46 | 0 | 0 | 0 | 0 |
| Not completed | 15 | 8 | 6 | 5 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 7 | 3 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 3 | 2 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Non-compliance | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 6 | 2 | 2 | 1 | 0 | 0 | 0 | 0 |
| Milestone | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | Part 1: Placebo + 26 Weeks Prednisone Taper | Part 1: Placebo + 52 Weeks Prednisone Taper | Part 2: No Tocilizumab (Placebo in Part 1) | Part 2: No Tocilizumab (Tocilizumab in Part 1) | Part 2: Tocilizumab (Placebo in Part 1) | Part 2: Tocilizumab (Tocilizumab in Part 1) |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 40 | 58 | 50 | 67 |
| Completed | 0 | 0 | 0 | 0 | 38 | 54 | 44 | 61 |
| Not completed | 0 | 0 | 0 | 0 | 2 | 4 | 6 | 6 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 2 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
Remission was defined as the absence of flare and normalization of the C-reactive protein (CRP) (less than \[\<\] 1 milligram per deciliter \[mg/dL\]). Sustained remission was defined as the absence of flare following induction of remission within 12 weeks of randomization and maintained up to Week 52. Flare was determined by the investigator and was defined as the recurrence of signs or symptoms of GCA and/or erythrocyte sedimentation rate (ESR) greater than or equal to (\>/=) 30 millimeters per hour (mm/hr) attributable to GCA. A single CRP elevation (\>/=1 mg/dL) was not considered as a sign of flare, unless the CRP remained elevated (\>/=1 mg/dL) at the next study visit.
| percentage of participants | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | Part 1: Placebo + 26 Weeks Prednisone Taper |
|---|---|---|---|
| Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 26 Weeks Prednisone Taper) | 56.0 | 53.1 | 14.0 |
Remission was defined as the absence of flare and normalization of the CRP (\<1 mg/dL). Sustained remission was defined as the absence of flare following induction of remission within 12 weeks of randomization and maintained up to Week 52. Flare was determined by the investigator and was defined as the recurrence of signs or symptoms of GCA and/or ESR \>/=30 mm/hr attributable to GCA. A single CRP elevation (\>/=1 mg/dL) was not considered as a sign of flare, unless the CRP remained elevated (\>/=1 mg/dL) at the next study visit.
| percentage of participants | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | Part 1: Placebo + 52 Weeks Prednisone Taper |
|---|---|---|---|
| Percentage of Participants in Sustained Remission at Week 52 (Tocilizumab + 26 Weeks Prednisone Taper Versus Placebo + 52 Weeks Prednisone Taper) | 56.0 | 53.1 | 17.6 |
Flare was determined by the investigator and was defined as the recurrence of signs or symptoms of GCA and/or ESR \>/=30 mm/hr attributable to GCA. Participants who withdrew from the study prior to Week 52 were censored from the time of withdrawal.
| days | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | Part 1: Placebo + 26 Weeks Prednisone Taper | Part 1: Placebo + 52 Weeks Prednisone Taper |
|---|---|---|---|---|
| Time to First GCA Disease Flare | NA (NA to NA) | NA (NA to NA) | 165.0 (120.0 to 260.0) | 295.0 (168.0 to NA) |
The median total cumulative prednisone dose over the 52 weeks for each treatment group and the corresponding 95% confidence intervals are presented.
| milligrams (mg) | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | Part 1: Placebo + 26 Weeks Prednisone Taper | Part 1: Placebo + 52 Weeks Prednisone Taper |
|---|---|---|---|---|
| Total Cumulative Prednisone Dose | 1862.00 (1582.0 to 1942.0) | 1862.00 (1568.0 to 2239.5) | 3296.00 (2729.5 to 4023.5) | 3817.50 (2817.5 to 4425.5) |
The SF-36 is a standardized questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical Component Score (PCS) and Mental Component Score (MCS). The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). A positive change from baseline indicates improvement. No imputation was used for missing data. Data was set to missing for participants who received escape therapy.
| units on a scale | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | Part 1: Placebo + 26 Weeks Prednisone Taper | Part 1: Placebo + 52 Weeks Prednisone Taper |
|---|---|---|---|---|
| PCS: Baseline (n=97,49,48,49) | 43.10 ± 9.43 | 40.62 ± 8.00 | 42.65 ± 10.87 | 41.12 ± 9.97 |
| PCS: Change at Week 52 (n=59,26,9,18) | 5.37 ± 7.38 | 2.71 ± 8.86 | 2.08 ± 12.11 | -2.80 ± 6.98 |
| MCS: Baseline (n=97,49,48,49) | 42.77 ± 12.43 | 47.67 ± 12.59 | 42.73 ± 12.13 | 40.45 ± 13.73 |
| MCS: Change at Week 52 (n=59,26,9,18) | 8.21 ± 10.35 | 1.98 ± 7.17 | 4.99 ± 7.54 | 2.60 ± 10.56 |
Participants assessed their current disease activity on a 0-100 millimeter (mm) VAS, where 0 mm = no disease activity and 100 mm = maximum disease activity. A negative change from baseline indicates improvement.
| mm | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | Part 1: Placebo + 26 Weeks Prednisone Taper | Part 1: Placebo + 52 Weeks Prednisone Taper |
|---|---|---|---|---|
| Baseline (n=100,49,49,51) | 43.61 ± 25.66 | 46.65 ± 25.60 | 35.73 ± 28.15 | 47.78 ± 27.80 |
| Change at Week 52 (n=60,26,11,18) | -19.68 ± 33.64 | -22.69 ± 22.41 | -8.45 ± 24.81 | -10.00 ± 35.12 |
AUCtau is the model-predicted area under the tocilizumab serum concentration versus time curve from time zero to the end of dosing interval. AUCtau is measured in microgram\*day per milliliter (mcg\*day/mL).
| mcg*day/mL | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper |
|---|---|---|
| Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) at Steady State of Tocilizumab | 499.2 ± 210.4 | 227.2 ± 165.4 |
Cmax,ss is maximum model-predicted serum steady state concentration of tocilizumab measured in micrograms per milliliter (mcg/mL).
| mcg/mL | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper |
|---|---|---|
| Maximum Serum Concentration at Steady State (Cmax,ss) of Tocilizumab | 73 ± 30.4 | 19.3 ± 12.8 |
Cmin,ss is minimum model-predicted serum steady state concentration of tocilizumab measured in mcg/mL.
| mcg/mL | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper |
|---|---|---|
| Minimum Serum Concentration at Steady State (Cmin,ss) of Tocilizumab | 68.1 ± 29.5 | 11.1 ± 10.3 |
Ctrough is minimum observed serum concentration of tocilizumab measured in mcg/mL.
| mcg/mL | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper |
|---|---|---|
| Baseline (n= 99, 48) | 0.07 ± 0.72 | 0.00 ± 0.02 |
| Week 52 (n= 72, 33) | 67.93 ± 34.40 | 12.22 ± 10.02 |
| picograms per milliliter (pg/mL) | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | Part 1: Placebo + 26 Weeks Prednisone Taper | Part 1: Placebo + 52 Weeks Prednisone Taper |
|---|---|---|---|---|
| Baseline (n=91,44,50,47) | 8.79 ± 10.01 | 16.29 ± 31.23 | 12.73 ± 18.04 | 8.31 ± 9.47 |
| Week 52 (n=69,32,28,30) | 65.99 ± 84.92 | 52.70 ± 33.10 | 35.96 ± 149.65 | 10.85 ± 15.17 |
| nanograms per milliliter (ng/mL) | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | Part 1: Placebo + 26 Weeks Prednisone Taper | Part 1: Placebo + 52 Weeks Prednisone Taper |
|---|---|---|---|---|
| Baseline (n=99,48,50,50) | 51.34 ± 61.98 | 50.82 ± 63.51 | 42.07 ± 11.32 | 40.37 ± 10.84 |
| Week 52 (n=73,33,33,31) | 600.53 ± 217.52 | 464.30 ± 153.64 | 76.44 ± 149.20 | 64.80 ± 105.13 |
ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hr. A higher rate is consistent with inflammation.
| mm/hr | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | Part 1: Placebo + 26 Weeks Prednisone Taper | Part 1: Placebo + 52 Weeks Prednisone Taper |
|---|---|---|---|---|
| Baseline (n=99,49,50,51) | 19.00 ± 61.98 | 15.00 ± 63.51 | 23.00 ± 11.32 | 20.00 ± 10.84 |
| Week 52 (n=76,35,35,33) | 3.00 (2.00 to 5.00) | 5.00 (2.00 to 7.00) | 20.00 (11.00 to 36.00) | 24.00 (10.00 to 37.00) |
The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.
| milligrams per liter (mg/L) | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | Part 1: Placebo + 26 Weeks Prednisone Taper | Part 1: Placebo + 52 Weeks Prednisone Taper |
|---|---|---|---|---|
| Baseline (n=100,49,50,51) | 3.67 ± 61.98 | 4.52 ± 63.51 | 3.64 ± 11.32 | 3.56 ± 10.84 |
| Week 52 (n=76,35,35,33) | 0.30 (0.20 to 0.59) | 0.33 (0.20 to 0.72) | 4.90 (2.25 to 9.25) | 8.12 (2.02 to 14.40) |
All samples were tested by screening assay, and those samples that were positive were further analyzed by a confirmation assay to confirm specificity. Percentage of participants who has a positive confirmation assay result any time after the initial drug administration with a negative confirmation assay result at baseline was reported.
| percentage of participants | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | Part 1: Placebo + 26 Weeks Prednisone Taper | Part 1: Placebo + 52 Weeks Prednisone Taper |
|---|---|---|---|---|
| Percentage of Participants With Anti-Tocilizumab Antibodies | 1.1 | 6.5 | 2.0 | 2.1 |
Collected over Up to 156 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | — | 15/100 (15%) | 87/100 (87%) |
| Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | — | 7/49 (14.3%) | 44/49 (89.8%) |
| Part 1: Placebo + 26 Weeks Prednisone Taper | — | 11/50 (22%) | 47/50 (94%) |
| Part 1: Placebo + 52 Weeks Prednisone Taper | — | 13/51 (25.5%) | 44/51 (86.3%) |
| Part 2: No Tocilizumab (Placebo in Part 1) | — | 7/40 (17.5%) | 33/40 (82.5%) |
| Part 2: No Tocilizumab (Tocilizumab in Part 1) | — | 11/58 (19%) | 50/58 (86.2%) |
| Part 2: Tocilizumab (Placebo in Part 1) | — | 18/50 (36%) | 44/50 (88%) |
| Part 2: Tocilizumab (Tocilizumab in Part 1) | — | 23/67 (34.3%) | 61/67 (91%) |
| Event | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | Part 1: Placebo + 26 Weeks Prednisone Taper | Part 1: Placebo + 52 Weeks Prednisone Taper | Part 2: No Tocilizumab (Placebo in Part 1) | Part 2: No Tocilizumab (Tocilizumab in Part 1) | Part 2: Tocilizumab (Placebo in Part 1) | Part 2: Tocilizumab (Tocilizumab in Part 1) |
|---|---|---|---|---|---|---|---|---|
| Temporal arteritisVascular disorders | 1/100 | 1/49 | 1/50 | 1/51 | 1/40 | 0/58 | 2/50 | 3/67 |
| UrosepsisInfections and infestations | 1/100 | 0/49 | 0/50 | 0/51 | 0/40 | 0/58 | 2/50 | 0/67 |
| Cerebrovascular accidentNervous system disorders | 0/100 | 0/49 | 0/50 | 0/51 | 0/40 | 0/58 | 2/50 | 0/67 |
| GastroenteritisInfections and infestations | 1/100 | 0/49 | 0/50 | 2/51 | 0/40 | 1/58 | 0/50 | 0/67 |
| Herpes zosterInfections and infestations | 1/100 | 0/49 | 0/50 | 2/51 | 0/40 | 0/58 | 0/50 | 0/67 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/100 | 0/49 | 0/50 | 1/51 | 0/40 | 1/58 | 0/50 | 2/67 |
| HaematomaVascular disorders | 0/100 | 0/49 | 0/50 | 0/51 | 0/40 | 0/58 | 0/50 | 2/67 |
| GlaucomaEye disorders | 0/100 | 0/49 | 1/50 | 0/51 | 1/40 | 0/58 | 0/50 | 0/67 |
| SyncopeNervous system disorders | 0/100 | 0/49 | 1/50 | 0/51 | 1/40 | 1/58 | 0/50 | 1/67 |
| Cardiac failureCardiac disorders | 0/100 | 0/49 | 0/50 | 1/51 | 1/40 | 0/58 | 0/50 | 1/67 |
| Event | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | Part 1: Placebo + 26 Weeks Prednisone Taper | Part 1: Placebo + 52 Weeks Prednisone Taper | Part 2: No Tocilizumab (Placebo in Part 1) | Part 2: No Tocilizumab (Tocilizumab in Part 1) | Part 2: Tocilizumab (Placebo in Part 1) | Part 2: Tocilizumab (Tocilizumab in Part 1) |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 29/100 | 12/49 | 9/50 | 13/51 | 5/40 | 13/58 | 14/50 | 22/67 |
| HeadacheNervous system disorders | 27/100 | 10/49 | 16/50 | 12/51 | 2/40 | 8/58 | 8/50 | 6/67 |
| Oedema peripheralGeneral disorders | 16/100 | 12/49 | 8/50 | 6/51 | 1/40 | 2/58 | 5/50 | 4/67 |
| DizzinessNervous system disorders | 6/100 | 10/49 | 6/50 | 8/51 | 2/40 | 0/58 | 5/50 | 4/67 |
| Urinary tract infectionInfections and infestations | 10/100 | 4/49 | 2/50 | 4/51 | 1/40 | 4/58 | 10/50 | 10/67 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 13/100 | 8/49 | 10/50 | 8/51 | 7/40 | 10/58 | 10/50 | 12/67 |
| Back painMusculoskeletal and connective tissue disorders | 14/100 | 7/49 | 7/50 | 10/51 | 3/40 | 4/58 | 8/50 | 7/67 |
| DiarrhoeaGastrointestinal disorders | 12/100 | 3/49 | 8/50 | 5/51 | 2/40 | 2/58 | 7/50 | 5/67 |
| FatigueGeneral disorders | 8/100 | 5/49 | 8/50 | 3/51 | 2/40 | 2/58 | 6/50 | 6/67 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 7/100 | 4/49 | 4/50 | 8/51 | 2/40 | 2/58 | 2/50 | 4/67 |
Safety Population included all participants who received at least one administration of study drug and provided at least one post-dose safety assessment.
| Age, Continuous(years) | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | Part 1: Placebo + 26 Weeks Prednisone Taper | Part 1: Placebo + 52 Weeks Prednisone Taper | Total |
|---|---|---|---|---|---|
| Mean | 69.5 ± 8.50 | 69.4 ± 8.29 | 69.3 ± 8.14 | 67.8 ± 7.70 | 69.1 ± 8.21 |
| Sex: Female, Male(Participants) | Part 1: Tocilizumab qw + 26 Weeks Prednisone Taper | Part 1: Tocilizumab q2w + 26 Weeks Prednisone Taper | Part 1: Placebo + 26 Weeks Prednisone Taper | Part 1: Placebo + 52 Weeks Prednisone Taper | Total |
|---|---|---|---|---|---|
| Female | 78 | 34 | 38 | 37 | 187 |
| Male | 22 | 15 | 12 | 14 | 63 |
Ran from Jul 2013 to primary completion in Apr 2016, 32 months.
Results were first posted in May 2017, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tocilizumab · Prednisone